College of Basic Medical Sciences and Department of Pathology, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.
Department of Pathology, First Chengdu Renmin Hospital, Chengdu, Sichuan, China.
Mol Carcinog. 2018 Feb;57(2):159-166. doi: 10.1002/mc.22740. Epub 2017 Dec 5.
TNFAIP8 is associated with prognosis of several human malignancies. However, the molecular mechanism of TNFAIP8 in lung cancer remains unknown. In our study, we found TNFAIP8 could enhance TEAD luciferase activity and inhibits the activity of Hippo pathway. TNFAIP8 also increased cyclin D1, CDK6, and decreased p27 in lung cancer cells. In addition, TNFAIP8 increased total YAP protein and promoted nuclear localization of YAP. More importantly, YAP depletion blocked the role of TNFAIP8 on cell cycle-related proteins and TEAD luciferase activity, revealing that TNFAIP8 regulates Hippo pathway in a YAP-dependend manner. Further experiments identified that TNFAIP8 depletion enhanced LATS1 phosphorylation and TNFAIP8 overexpression decreased phosphorylated LAST1 level. LATS1 siRNA treatment reversed the effects of TNFAIP8 plasmid or siRNA on cell cycle proteins. Besides, immunofluorescence and co-immunoprecipitation demonstrated the interaction between TNFAIP8 and LATS1 in H460 and H1299 cells, suggesting that TNFAIP8 regulates Hippo signaling through its interaction with LATS1. Colony formation assays and transwell assays showed that YAP or LATS1 depletion reversed the positive effect of TNFAIP8 on cell proliferation and invasion. TNFAIP8 overexpression could increase MMP-7 and TNFAIP8 depletion could decrease MMP-7 at both protein and mRNA levels, without significant changes of E-cadherin, N-cadherin, and Vimentin. Collectively, the present study provides a novel finding that TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer. TNFAIP8 may serve as a candidate biomarker for poor prognosis and a target for new therapies.
肿瘤坏死因子α诱导蛋白 8(TNFAIP8)与多种人类恶性肿瘤的预后相关。然而,TNFAIP8 在肺癌中的分子机制尚不清楚。在本研究中,我们发现 TNFAIP8 可增强 TEAD 荧光素酶活性并抑制 Hippo 通路活性。TNFAIP8 还增加了肺癌细胞中的细胞周期蛋白 D1、CDK6,并降低了 p27 的表达。此外,TNFAIP8 增加了 YAP 的总蛋白水平,并促进了 YAP 的核定位。更为重要的是,YAP 的耗竭阻断了 TNFAIP8 对细胞周期相关蛋白和 TEAD 荧光素酶活性的作用,表明 TNFAIP8 以 YAP 依赖的方式调节 Hippo 通路。进一步的实验确定,TNFAIP8 的耗竭增强了 LATS1 的磷酸化,而 TNFAIP8 的过表达降低了磷酸化 LATS1 的水平。LATS1 siRNA 处理逆转了 TNFAIP8 质粒或 siRNA 对细胞周期蛋白的作用。此外,免疫荧光和共免疫沉淀实验证明了 TNFAIP8 与 LATS1 在 H460 和 H1299 细胞中的相互作用,表明 TNFAIP8 通过与 LATS1 的相互作用来调节 Hippo 信号。集落形成实验和 Transwell 实验表明,YAP 或 LATS1 的耗竭逆转了 TNFAIP8 对细胞增殖和侵袭的正向作用。TNFAIP8 的过表达可增加 MMP-7 的表达,而 TNFAIP8 的耗竭可降低 MMP-7 的蛋白和 mRNA 水平,而 E-钙黏蛋白、N-钙黏蛋白和波形蛋白没有明显变化。总之,本研究提供了一个新的发现,即 TNFAIP8 通过与 LATS1 相互作用来调节 Hippo 通路,从而促进肺癌细胞的增殖和侵袭。TNFAIP8 可能成为预后不良的候选生物标志物和新疗法的靶点。